Arrowhead Pharmaceuticals, Inc. (ARWR) has disclosed a new risk, in the Sales & Marketing category.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The reliance of Arrowhead Pharmaceuticals, Inc. on Vanscoy Rare Pharmacy for the distribution of plozasiran presents a significant business risk, as any financial instability or altered buying patterns at Vanscoy could negatively impact the company’s revenues and financial health. Such fluctuations might arise from various factors, including seasonality or changes in pricing strategies, potentially leading to unforeseen disruptions in the supply chain. This dependency underscores the vulnerability of Arrowhead Pharmaceuticals to external business conditions beyond its direct control. The company must remain vigilant to these risks to safeguard its operational stability and profitability.
The average ARWR stock price target is $40.56, implying 55.11% upside potential.
To learn more about Arrowhead Pharmaceuticals, Inc.’s risk factors, click here.